Clinical Trial Detail

NCT ID NCT01572727
Title A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Buparlisib + Paclitaxel

Paclitaxel

Age Groups: adult

Additional content available in CKB BOOST